Abstract
PurposeTAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Efficacy and safety of TAS-102 in patients with metastatic colorectal cancer (mCRC) refractory or intolerant to standard therapies were evaluated in the phase 3 RECOURSE trial. Results of RECOURSE demonstrated significant improvement in overall survival (OS) and progression-free survival (PFS) with TAS-102 versus placebo [hazard ratio (HR) = 0.68 and 0.48 for OS and PFS, respectively; both P < 0.001]. The current analysis evaluates efficacy and safety of TAS-102 in the RECOURSE Spanish subgroup.MethodsPrimary and key secondary endpoints were evaluated in a post hoc analysis of the RECOURSE Spanish subgroup, using univariate and multivariate analyses. Safety and tolerability were reported with descriptive statistics.ResultsThe RECOURSE Spanish subgroup included 112 patients (mean age 61 years, 62 % male). Median OS was 6.8 months in the TAS-102 group (n = 80) versus 4.6 months in the placebo group (n = 32) [HR = 0.47; 95 % confidence interval (CI): 0.28–0.78; P = 0.0032). Median PFS was 2.0 months in the TAS-102 group and 1.7 months in the placebo group (HR = 0.47; 95 % CI: 0.30–0.74; P = 0.001). Eighty (100 %) TAS-102 versus 31 (96.9 %) placebo patients had adverse events (AEs). The most common drug-related ≥Grade 3 AE was neutropenia (40 % TAS-102 versus 0 % placebo). There was 1 (1.3 %) case of febrile neutropenia in the TAS-102 group versus none in the placebo group.ConclusionsIn the RECOURSE Spanish subgroup, TAS-102 was associated with significantly improved OS and PFS versus placebo, consistent with the overall RECOURSE population. No new safety signals were identified.ClinicalTrials.gov study numberNCT01607957
Highlights
TAS-102 is an oral combination treatment consisting of trifluridine (FTD), a thymidine-based nucleoside analog, and tipiracil hydrochloride (TPI), at a molar ratio of 1:0.5
The current analysis evaluates efficacy and safety of TAS-102 in the RECOURSE Spanish subgroup
In the RECOURSE Spanish subgroup, TAS102 was associated with significantly improved overall survival (OS) and progression-free survival (PFS) versus placebo, consistent with the overall RECOURSE population
Summary
TAS-102 is an oral combination treatment consisting of trifluridine (FTD), a thymidine-based nucleoside analog, and tipiracil hydrochloride (TPI), at a molar ratio of 1:0.5 (weight ratio: 1:0.471). It is approved for use in Japan and the United States, and has been recently approved in Europe. The primary cytotoxic mechanism of oral FTD is through incorporation into DNA following phosphorylation by thymidine kinase, leading to DNA dysfunction (Fig. 1) [1, 2] This mechanism is distinct from that of 5-fluorouracil (5-FU) and other fluoropyrimidines that produce their cytotoxic effects through inhibition of thymidylate synthase. The combination of these two agents makes TAS-102 an attractive candidate for treatment of patients with metastatic colorectal cancer (mCRC) who are refractory to fluoropyrimidines [5]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
